NTHI’s Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results

DENVER, Aug. 17, 2026 (GLOBE NEWSWIRE) -- There is a tendency to think of a Nasdaq listing as simply a better place for a stock to trade. For NeOnc Technologies Holdings (NASDAQ: NTHI), however, the Nasdaq Global Market listing has become considerably more interesting following NeOnc’s Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma.

The company reported a six-month progression-free survival rate of 48.9%, nearly 2.5 times the 20% historical benchmark, with a reported p-value of 0.0047. NeOnc also reported median overall survival of approximately 26.1 months, while six-, 12- and 24-month overall-survival rates were approximately 86.7%, 60.9% and 54.1%, respectively. The study was open-label and single-arm, so the results should be viewed as an encouraging clinical signal rather than definitive proof of efficacy that would ordinarily come from a randomized confirmatory trial.